306 related articles for article (PubMed ID: 12696003)
1. Susceptibility of herpes simplex virus isolates to nucleoside analogues and the proportion of nucleoside-resistant variants after repeated topical application of penciclovir to recurrent herpes labialis.
Shin YK; Weinberg A; Spruance S; Bernard M; Bacon TH; Boon RJ; Levin MJ
J Infect Dis; 2003 Apr; 187(8):1241-5. PubMed ID: 12696003
[TBL] [Abstract][Full Text] [Related]
2. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
Sarisky RT; Bacon TH; Boon RJ; Duffy KE; Esser KM; Leary J; Locke LA; Nguyen TT; Quail MR; Saltzman R
Arch Virol; 2003 Sep; 148(9):1757-69. PubMed ID: 14505088
[TBL] [Abstract][Full Text] [Related]
3. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
[TBL] [Abstract][Full Text] [Related]
4. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial.
Lin L; Chen XS; Cui PG; Wang JB; Guo ZP; Lu NZ; Bi ZG; Jia H; Yang XY;
J Dermatolog Treat; 2002 Jun; 13(2):67-72. PubMed ID: 12060504
[TBL] [Abstract][Full Text] [Related]
5. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis.
Duan R; de Vries RD; van Dun JM; van Loenen FB; Osterhaus AD; Remeijer L; Verjans GM
J Infect Dis; 2009 Nov; 200(9):1402-14. PubMed ID: 19795980
[TBL] [Abstract][Full Text] [Related]
6. Factors that affect in vitro measurement of the susceptibility of herpes simplex virus to nucleoside analogues.
Weinberg A; Leary JJ; Sarisky RT; Levin MJ
J Clin Virol; 2007 Feb; 38(2):139-45. PubMed ID: 17169605
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of topical acyclovir monophosphate, acyclovir, or penciclovir in orofacial HSV-1 infections of mice and genital HSV-2 infections of guinea pigs.
Kern ER; Palmer J; Szczech G; Painter G; Hostetler KY
Nucleosides Nucleotides Nucleic Acids; 2000; 19(1-2):501-13. PubMed ID: 10772730
[TBL] [Abstract][Full Text] [Related]
8. Surveillance for antiviral-agent-resistant herpes simplex virus in the general population with recurrent herpes labialis.
Bacon TH; Boon RJ; Schultz M; Hodges-Savola C
Antimicrob Agents Chemother; 2002 Sep; 46(9):3042-4. PubMed ID: 12183267
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
10. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
Okuda T; Kurokawa M; Matsuo K; Honda M; Niimura M; Shiraki K
J Med Virol; 2004 Jan; 72(1):112-20. PubMed ID: 14635018
[TBL] [Abstract][Full Text] [Related]
11. Recurrent herpes labialis: efficacy of topical therapy with penciclovir compared with acyclovir (aciclovir).
Femiano F; Gombos F; Scully C
Oral Dis; 2001 Jan; 7(1):31-3. PubMed ID: 11354919
[TBL] [Abstract][Full Text] [Related]
12. Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis.
Sarisky RT; Bacon T; Boon R; Locke L; Nguyen TT; Leary J; Esser K; Saltzman R
Antimicrob Agents Chemother; 2002 Sep; 46(9):2848-53. PubMed ID: 12183237
[TBL] [Abstract][Full Text] [Related]
13. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
14. Penciclovir cream--improved topical treatment for herpes simplex infections.
Schmid-Wendtner MH; Korting HC
Skin Pharmacol Physiol; 2004; 17(5):214-8. PubMed ID: 15452407
[TBL] [Abstract][Full Text] [Related]
15. An update on short-course intermittent and prevention therapies for herpes labialis.
Gilbert S; Corey L; Cunningham A; Malkin JE; Stanberry L; Whitley R; Spruance S
Herpes; 2007 Jun; 14 Suppl 1():13A-18A. PubMed ID: 17877887
[TBL] [Abstract][Full Text] [Related]
16. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.
Spruance SL; Rea TL; Thoming C; Tucker R; Saltzman R; Boon R
JAMA; 1997 May; 277(17):1374-9. PubMed ID: 9134943
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus resistance to acyclovir: clinical relevance.
Pottage JC; Kessler HA
Infect Agents Dis; 1995 Sep; 4(3):115-24. PubMed ID: 8548189
[TBL] [Abstract][Full Text] [Related]
18. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients.
Stránská R; van Loon AM; Polman M; Beersma MF; Bredius RG; Lankester AC; Meijer E; Schuurman R
Antivir Ther; 2004 Aug; 9(4):565-75. PubMed ID: 15456088
[TBL] [Abstract][Full Text] [Related]
19. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients.
Levin MJ; Bacon TH; Leary JJ
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S248-57. PubMed ID: 15494896
[TBL] [Abstract][Full Text] [Related]
20. Topical acyclovir in the treatment of recurrent herpes simplex virus infections.
Kinghorn GR
Scand J Infect Dis Suppl; 1985; 47():58-62. PubMed ID: 3912972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
